Case Report
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jan 28, 2017; 9(3): 161-166
Published online Jan 28, 2017. doi: 10.4254/wjh.v9.i3.161
Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin
Maria Pilar Ballester-Ferré, Fernando Martínez, Natalia Garcia-Gimeno, Francisco Mora, Miguel A Serra
Maria Pilar Ballester-Ferré, Gastroenterology and Hepatology Department, University Clinic Hospital of Valencia, University of Valencia, 46010 Valencia, Spain
Maria Pilar Ballester-Ferré, Natalia Garcia-Gimeno, Francisco Mora, Miguel A Serra, Digestive Medicine Department, University Clinic Hospital of Valencia, University of Valencia, 46010 Valencia, Spain
Fernando Martínez, Internal Medicine Department, University Clinic Hospital of Valencia, University of Valencia, 46010 Valencia, Spain
Author contributions: Ballester-Ferré MP and Martínez F designed the case; García-Gimeno N performed the research; Ballester-Ferré MP wrote the manuscript; Mora F and Serra MA performed a critical revision.
Institutional review board statement: This case report was exempt from the Institutional Review Board standards at University Clinic Hospital of Valencia.
Informed consent statement: All study participants provided informed consent prior to study enrollment.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Maria Pilar Ballester-Ferré, MD, Gastroenterology and Hepatology Department, University Clinic Hospital of Valencia, University of Valencia, Blasco Ibañez, 17, 46010 Valencia, Spain. mapibafe@gmail.com
Telephone: +34-657-972572
Received: July 14, 2016
Peer-review started: July 18, 2016
First decision: August 4, 2016
Revised: September 3, 2016
Accepted: October 17, 2016
Article in press: October 18, 2016
Published online: January 28, 2017
Processing time: 192 Days and 1.3 Hours
Core Tip

Core tip: Cases of tuberculosis (TB) infection have been identified with α-interferon-based therapy and the triple therapy with pegylated-interferon, ribavirin and boceprevir or telaprevir. This is the first case of a TB infection during treatment with sofosbuvir/ledipasvir plus ribavirin. It is relevant to increase awareness of TB due to its variety of symptoms, which can be confused with those associated to the hepatitis C virus or the antiviral treatment. Considering the impaired immune system of cirrhotic patients and that these drugs arrived slightly more than one year ago it is important to be conscious of the potential events that can be related with the treatment.